Grunenthal GmbH - Product Pipeline Review - 2014

Published: Jul, 2014 | Pages: 48 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Grunenthal GmbH - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Grunenthal GmbH - Product Pipeline Review - 2014', provides an overview of the Grunenthal GmbH's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Grunenthal GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Grunenthal GmbH including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Grunenthal GmbH's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Grunenthal GmbH's pipeline products

Reasons to buy

- Evaluate Grunenthal GmbH's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Grunenthal GmbH in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Grunenthal GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Grunenthal GmbH and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Grunenthal GmbH
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Grunenthal GmbH and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Grunenthal GmbH Snapshot 6
Grunenthal GmbH Overview 6
Key Information 6
Key Facts 6
Grunenthal GmbH - Research and Development Overview 7
Key Therapeutic Areas 7
Grunenthal GmbH - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Grunenthal GmbH - Pipeline Products Glance 15
Grunenthal GmbH - Late Stage Pipeline Products 15
Phase III Products/Combination Treatment Modalities 15
Grunenthal GmbH - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Grunenthal GmbH - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Discovery Products/Combination Treatment Modalities 19
Grunenthal GmbH - Unknown Stage Pipeline Products 20
Unknown Products/Combination Treatment Modalities 20
Grunenthal GmbH - Drug Profiles 21
cebranopadol 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
tapentadol hydrochloride 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
tapentadol hydrochloride ER 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
GRT-6010 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
GRT-6011 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Small Molecule 1 for Pain 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecule 2 for Pain 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
GRTTA-2210 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
RO-656570 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecule to Antagonize Bradykinin B1 Receptor for Chronic Inflammation 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecule-3 for Pain 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecule for Pain 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
(oxycodone + naloxone) 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
GRT-6006 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Grunenthal GmbH - Pipeline Analysis 38
Grunenthal GmbH - Pipeline Products by Target 38
Grunenthal GmbH - Pipeline Products by Route of Administration 39
Grunenthal GmbH - Pipeline Products by Molecule Type 40
Grunenthal GmbH - Pipeline Products by Mechanism of Action 41
Grunenthal GmbH - Recent Pipeline Updates 42
Grunenthal GmbH - Dormant Projects 44
Grunenthal GmbH - Company Statement 45
Grunenthal GmbH - Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 48
Disclaimer 48

List of Tables
Grunenthal GmbH, Key Information 6
Grunenthal GmbH, Key Facts 6
Grunenthal GmbH - Pipeline by Indication, 2014 9
Grunenthal GmbH - Pipeline by Stage of Development, 2014 10
Grunenthal GmbH - Monotherapy Products in Pipeline, 2014 11
Grunenthal GmbH - Combination Treatment Modalities in Pipeline, 2014 12
Grunenthal GmbH - Partnered Products in Pipeline, 2014 13
Grunenthal GmbH - Partnered Products/ Combination Treatment Modalities, 2014 14
Grunenthal GmbH - Phase III, 2014 15
Grunenthal GmbH - Phase II, 2014 16
Grunenthal GmbH - Phase I, 2014 17
Grunenthal GmbH - Preclinical, 2014 18
Grunenthal GmbH - Discovery, 2014 19
Grunenthal GmbH - Unknown, 2014 20
Grunenthal GmbH - Pipeline by Target, 2014 38
Grunenthal GmbH - Pipeline by Route of Administration, 2014 39
Grunenthal GmbH - Pipeline by Molecule Type, 2014 40
Grunenthal GmbH - Pipeline Products by Mechanism of Action, 2014 41
Grunenthal GmbH - Recent Pipeline Updates, 2014 42
Grunenthal GmbH - Dormant Developmental Projects,2014 44
Grunenthal GmbH, Other Locations 46
Grunenthal GmbH, Subsidiaries 46